The dramatic swing in gross margin, from -32.2% to 33.4% within two quarters, suggests that the company's profitability is highly sensitive to both product mix and NdPr pricing, but the underlying cost structure remains heavy. Operating margin improved to -13.5% in 2026Q2 from -125.2% in 2025Q3, yet it remains deeply negative, implying that SG&A and other operating costs are scaling with revenue, preventing operating leverage. The persistence of negative margins despite revenue growth of 89% year-over-year indicates that the company is still in a ramp-up phase where commissioning costs and fixed overheads outpace the contribution from higher volumes.

ROIC has hovered near zero or negative over the past ten quarters, with the best quarter at -0.1% in 2025Q4, suggesting that the company is not compounding returns on its invested capital. The asset base has grown significantly, with net PPE up 33% year-over-year to $1.6B, but the negative ROIC implies that the incremental capital is not yet productive. The transition from a pure concentrate seller to a refined products and magnetics producer requires substantial upfront investment, and the current returns suggest that the market is pricing in future success rather than current profitability.

The cash conversion cycle has lengthened from 192 days in 2024Q1 to 256 days in 2026Q2, primarily due to a rise in days inventory outstanding from 172 to 216, which suggests that the company is building inventory ahead of sales or facing slower inventory turnover. Days sales outstanding also increased to 91 days in 2026Q2 from 66 days in 2024Q1, indicating that customers are taking longer to pay, possibly due to the mix of customers or contractual terms. The negative free cash flow margin of -2.1% in 2026Q2, despite a positive operating cash flow, underscores that working capital and capex are consuming cash faster than operations generate it.

The improvement in debt-to-equity from 0.83 to 0.48 is largely due to equity doubling to $2.0B, driven by external capital raises, rather than debt reduction. Interest coverage turned negative in 2026Q2 at -2.02, down from 2.07 in 2025Q4, indicating that operating income is insufficient to cover interest expenses, which may raise refinancing risk if cash reserves deplete. The high cash balance of $1.16B provides a buffer, but the rapid drawdown to $429.1M in 2026Q2 suggests that the company is relying on debt and equity markets to fund its expansion, which could become more costly in a rising rate environment.

The current ratio of 9.51 appears robust, but it is inflated by the large cash balance that is being consumed at an accelerating pace. The quick ratio of 8.56 suggests that inventory is not a major liquidity concern, but the negative free cash flow of -$223.5M in 2026Q2 indicates that the company is burning through its cash reserves to fund capital expenditures. If NdPr prices remain weak and the Stage II and III facilities continue to require heavy investment, the liquidity position could deteriorate quickly, potentially forcing the company to raise additional capital or slow its expansion plans.